Idexx Laboratories

At a glance

Idexx Laboratories reported 2025 revenue of $4.3B, up 10.4% from $3.9B in 2024. Over 4 years since 2021 ($3.22B), that is growth of about 7.6% a year. Operating margin was 31.6%, up from 29% in 2021. 2025 was the highest revenue year in this period.

In the last 12 months 6 insiders reported 0 open-market purchases and 8 sales ($37.7M). None of the sales were flagged as 10b5-1 plan trades. The largest was a sale of $15.3M by President and CEO Jonathan Jay Mazelsky on Mar 2, 2026.

Idexx Laboratories filed 9 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), officer or director change (3), bylaws or fiscal year change (1) and shareholder vote results (1). The latest officer or director change was reported on Mar 26, 2026. It reported a material agreement or a completed acquisition or disposal 1 time.

3 of the 20 investors tracked here held Idexx Laboratories at the last quarter end, worth $143.5M combined. It is the largest weight for Renaissance Technologies (0.1% of its portfolio), followed by Bridgewater Associates (0.1%). Added: Renaissance Technologies, Bridgewater Associates and National Pension Service (Korea).

Annual results

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.